Verona Pharma to Report Third Quarter 2024 Financial Results and Provide Corporate Update
21 10월 2024 - 3:00PM
Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”)
announces that it will report its financial results for the third
quarter ended September 30, 2024 on Monday, November 4, 2024 and
host an investment community conference call at 9:00 a.m. EDT /
2:00 p.m. GMT to discuss these financial results and provide a
corporate update.
To participate, please dial one of the following
numbers and ask to join the Verona Pharma call:
- +1-833-816-1396 for callers in the
United States
- +1-412-317-0489
for international callers
A live webcast will be available on the Events
and Presentations link on the Investors page of the Company’s
website, www.veronapharma.com, and the audio replay will be
available for 90 days.
For further information please contact:
Verona Pharma plc |
Tel: +1-844-341-9901 |
Victoria Stewart, Senior Director of Investor Relations and
Communications |
IR@veronapharma.com |
Argot PartnersUS Investor Enquiries |
Tel: +1-212-600-1902verona@argotpartners.com |
Ten Bridge CommunicationsInternational / US Media
Enquiries |
Tel: +1-312-523-5016tbcverona@tenbridgecommunications.com |
Leslie Humbel |
|
About Verona Pharma
Verona Pharma is a biopharmaceutical company
focused on developing and commercializing innovative therapies for
the treatment of chronic respiratory diseases with significant
unmet medical needs. Ohtuvayre™ (ensifentrine) is the
Company’s first commercial product and the first inhaled therapy
for the maintenance treatment of COPD that combines bronchodilator
and non-steroidal anti-inflammatory activities in one molecule.
Ensifentrine has potential applications in non-cystic fibrosis
bronchiectasis, cystic fibrosis, asthma and other respiratory
diseases. For more information, please
visit www.veronapharma.com.
Verona Pharma (NASDAQ:VRNA)
과거 데이터 주식 차트
부터 10월(10) 2024 으로 11월(11) 2024
Verona Pharma (NASDAQ:VRNA)
과거 데이터 주식 차트
부터 11월(11) 2023 으로 11월(11) 2024